Usage de substances chez des patients hospitalisés pour rechute schizophrénique : étude transversale

Background In addition to the biological plausibility widely described through a very large number of studies, the causal link between cannabis uses and schizophrenia disorders has become illicit internationally and given the scarcity of similar studies in Morocco. Our study consists of a prospective descriptive study in the psychiatric department of the Moulay ben Abdallah Hospital in Essaouira. The sample consisted of 95 patients diagnosed with schizophrenia according to the DSM5 criteria. The diagnostic assessment included the Positive and Negative Syndrome Scale to assess the severity of positive and negative symptoms of schizophrenia as well as the patient’s general psychopathology, the Clinician-Rated Dimensions of Psychosis Symptom Severity to assess the symptom severity of the psychotic dimensions according, and the Cannabis Abuse Screening Test to assess the extent of cannabis use. Results The mean age of the patients recruited in the study was 33.7 ± 9.37 years with a clear male predominance (p < 0.0001). Cannabis users compared to non-users were younger and comprised only men. Cannabis users also have a lower educational and economic level than non-users. Furthermore, a clear dose effect of cannabis uses on the onset of positive and negative symptoms of schizophrenia. The temporality criterion is clear in our study, since the predictivity of the parameter: “age of onset of cannabis use” is highly significant (p = 0.000). These results suggest that cannabis use can be considered as the most illicit risk factor for the development and/or onset of schizophrenia. Conclusions These results suggest that there is a causal relationship between cannabis use and/or dependence (problematic use) and the onset and/or worsening of schizophrenic disorder. This means that problematic cannabis use can be considered as a real risk factor for the emergence and development of schizophrenic disorder.

show abstract

Cannabis Use in Patients Hospitalized for Psychotic Andbipolar Disorders in the Psychiatry Department of a General Hospital

Hammani

Taoufik

Youssef

et al. 2022

IJAR

View full text Add to dashboard Cite

Le cannabis est la substance psychoactive illicite la plus consommée dans notre pays et dans le monde. Son impact négatif sur les troubles psychiatriques a été largement évoqué, mais peu d'études ont été réalisées dans notre contexte.฀ Objectifs : nous allons évaluer la prévalence de la consommation de cannabis chez des patients atteints de troubles psychotiques et bipolaires, et étudier son impact sur le nombre et la durée des hospitalisations.฀ Méthodologie : il s'agit d'une étude transversale rétrospective, menée sur 130 dossiers de patients hospitalisés au sein du service de psychiatrie d'un Hôpital général provincial, entre novembre 2018 et novembre 2020.฀ Résultats : L'âge moyen de notre population est de 28 ans ± 9,4, tous de sexe masculin, dont 58.9% sont atteints de troubles psychotiques et 41.1% sont atteints de troubles bipolaires. La prévalence de la consommation de cannabis est de 65,9 %, avec 65,8% pour les troubles psychotiques et 66% pour les troubles bipolaires. Le cannabis est associé à une hospitalisation plus longue de ces patients : 28,34 contre 19,43 jours (p=0,005), mais pas à un nombre plus important d'hospitalisations. Conclusion : la consommation de cannabis est très répandue parmi les patients atteints de troubles psychotiques et bipolaires. Nos résultats restent limités par le fait que nos patients sont généralement réhospitalisés dans d'autres structures de soins.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Usage de substances chez des patients hospitalisés pour rechute schizophrénique : étude transversale

Cited by 3 publications

References 32 publications

Schizophrénie et addictions : Étude exploratoire chez 106 patients suivis en consultation

Schizophrénie et addictions : Étude exploratoire chez 106 patients suivis en consultation

Cannabis and schizophrenia: characterisation of a risk factor in a sample of Moroccan patients hospitalised for psychosis

Cannabis Use in Patients Hospitalized for Psychotic Andbipolar Disorders in the Psychiatry Department of a General Hospital

Contact Info

Product

Resources

About